ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lilly buys into Centrexion pain drug

by Lisa M. Jarvis
June 1, 2019 | APPEARED IN VOLUME 97, ISSUE 22

Eli Lilly and Company will pay $47.5 million for the rights to Centrexion Therapeutics’ nonopioid chronic pain treatment, CNTX-0290. The small molecule, currently in Phase I trials, modulates the somatostatin receptor type 4, part of a protein family that dampens the activity of several types of pain receptors. Centrexion could get another $575 million in development and regulatory milestones and can buy into commercializing the drug in the US alongside Lilly.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment